Results 11 to 20 of about 43,499 (244)

Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer

Taiwanese Journal of Obstetrics & Gynecology, 2017
Chia-Hao Liu, Yi Chang
doaj   +3 more sources

Poly(ADP-Ribose) Polymerase Inhibitors [PDF]

Journal of Thoracic Oncology, 2010
This session not only described several poly(ADP-ribose) polymerase (PARP) inhibitors but also included talks on the science of nuclear excision repair, an oxidized glutathione, and a heat shock protein (HSP) 90 inhibitor. SUMMARY OF PRESENTATIONS Science of Nuclear Excision Repair Dr.
Garon, Edward B., Dubinett, Steven M.
openaire   +4 more sources

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report

Journal of Medical Case Reports, 2021
Background Homologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer.
Rosa Montero-Macias, Meriem Koual, Céline Crespel, Marie Aude Le Frére-Belda, Hélène Blons Hélène, Huyen-Thu Nguyen-Xuan, Simon Garinet, Géraldine Perkins, Vincent Balay, Catherine Durdux, Marie Florin, Hélène Péré, Anne-Sophie Bats   +12 more
doaj   +1 more source

Pyridazine Based Compounds with PARP-1 Inhibitory Activity

Archives of Pharmaceutical Sciences Ain Shams University, 2023
Pyridazine-containing compounds have been identified as potent PARP1 inhibitors. The PARP is a family of enzymes essential for many cellular processes such as DNA repair, genomic stability, and apoptosis, also known as poly(ADP-ribose) synthetases and ...
Norhan A. Abdelrahman, Mai Y. Jaballah, Ahmed A. Al-Karmalawy , Khaled A. M. Abouzid   +3 more
doaj   +1 more source

The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection

Journal of Infection in Developing Countries, 2022
Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.
Dimitra Ioanna Lampropoulou, Vanessa Meletia Bala, Eleni Zerva, Evangelia Pliakou, Dimitrios Filippou, Maria Gazouli, Gerasimos Aravantinos   +6 more
doaj   +1 more source

Adverse events of targeted therapies approved for women's cancers

International Journal of Women's Dermatology, 2021
Breast cancer and gynecologic cancers affect >3 million women worldwide each year. With advances in precision medicine, a growing number of targeted therapies have been approved recently, and new therapeutic classes have emerged, including cell cycle ...
Mathilde Saint-Ghislain, MD, Chloé Levenbruck, PhD, Audrey Bellesoeur, MD   +2 more
doaj   +1 more source

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer

BMC Cancer, 2020
Background Poly (ADP-ribose) polymerase inhibitors targeting BRCA1/2 mutations are available for treating patients with high-grade serous ovarian cancer.
Kyung Jin Eoh, Hye Min Kim, Jung-Yun Lee, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Eun Ji Nam   +6 more
doaj   +1 more source

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma [PDF]

Current Opinion in Oncology, 2014
In 2012, two publications revealed a particular sensitivity of Ewing sarcoma cells to the inhibition of poly(ADP-ribose) polymerase (PARP). This review updates the reader on PARP function, the development of PARP inhibitors (PARPi) and the evidence for targeting PARP in Ewing sarcoma.
Vormoor, Britta, Curtin, Nicola J.
openaire   +2 more sources

Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors

Basic & Clinical Pharmacology & Toxicology, 2023
AbstractPoly ADP‐ribose polymerase (PARP) inhibitors have been approved for the treatment of various cancers. They share a similar mechanism of action but have differences in pharmacokinetic characteristics and potential for drug–drug interactions (DDI).
Feng Deng, Johanna Sistonen, Mikko Neuvonen, Mikko Niemi   +3 more
openaire   +3 more sources

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents

Frontiers in Oncology, 2021
BackgroundPoly ADP-ribose glycohydrolase (PARG) is responsible for the catabolism of PARP-synthesized PAR to free ADP-ribose. Inhibition of PARG leads to DNA repair interruption and consequently induces cell death.
Emad Matanes, Emad Matanes, Vanessa M. López-Ozuna, David Octeau, Tahira Baloch, Florentin Racovitan, Amandeep Kaur Dhillon, Roy Kessous, Roy Kessous, Oded Raban, Oded Raban, Liron Kogan, Liron Kogan, Shannon Salvador, Shannon Salvador, Susie Lau, Susie Lau, Walter H. Gotlieb, Walter H. Gotlieb, Amber Yasmeen   +19 more
doaj   +1 more source